Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https: ...

LITTLE ROCK, Ark., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leader in artificial intelligence-driven advertising technology, will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, March 5, 2026. The Company will host a conference call at 4:15 p.m. Eastern Time that same day to discuss the results and provide a business update. Conference Call Details: Date: Thursday, March 5, 2026Time: 4:15 p.m. Eastern T ...

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. T ...

LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announces today that it will release its results for the three and twelve months ended December 31, 2025, after markets close in New York, on Wednesday, March 11, 2026. The next day, Thursday, March 12, 2026, at 9:00 A.M. E.T., the Company’s management team will host a Zoom conference ca ...

Core Insights - Inseego Corp. has announced the next generation of its cloud-based SaaS BSS platform, Inseego Subscribe, aimed at helping service providers effectively compete for complex enterprise and government customers [1][3] Group 1: Platform Features and Benefits - Inseego Subscribe is designed to help service providers economically manage the lifecycle of complex enterprise and government wireless customers, enabling efficient sales, onboarding, and operations [2][3] - The platform reduces customer acquisition costs, accelerates sales cycles, increases revenue, improves retention, and lowers ongoing support costs for high-value accounts [3][4] - It offers self-service capabilities for enterprise administrators, allowing them to manage governance, compliance, and operational controls without ongoing provider intervention [6] Group 2: Enhancements and Innovations - The updated release features a streamlined user experience with a redesigned UX that simplifies quoting, selling, and managing enterprise services through a CPQ-style interface [7] - Inseego Subscribe digitizes government contract line items, automating complex workflows and enabling service providers to scale SLED and Federal programs more efficiently [8] - A new API layer simplifies integration with carrier environments, reducing the time and effort required for onboarding new service providers [9][10] Group 3: Strategic Positioning - Inseego Subscribe is part of Inseego's evolution into a cloud-first wireless edge platform, combining subscriber lifecycle management with connectivity, security, and network management [12] - The platform is designed to turn enterprise cellular connectivity into a strategic advantage for service providers, enhancing their ability to deliver wireless solutions across various sectors [12] Group 4: Availability and Future Plans - The new version of Inseego Subscribe is set to be available in the second half of the year, with plans to showcase the platform at Mobile World Congress 2026 [13]

Company Overview - StepStone Group Inc. is a global private markets investment firm that provides customized investment solutions and advisory and data services to clients [2] - As of December 31, 2025, StepStone managed approximately $811 billion in total capital, which includes $220 billion in assets under management [2] - The firm's clients consist of large public and private pension funds, sovereign wealth funds, insurance companies, endowments, foundations, family offices, and high-net-worth individuals [2] Upcoming Events - Scott Hart, CEO, and Mike McCabe, Head of Strategy, are scheduled to present at the RBC Capital Markets Global Financial Institutions Conference on March 10, 2026, at 4:00 pm ET [1] - A live webcast and replay of the presentation will be available on the StepStone website [1]

CMD Active bid pipeline exceeds $160 million—the largest in company history—across multifamily, tract home, custom home, and commercial segmentsNEW YORK, NY, Feb. 26, 2026 (GLOBE NEWSWIRE) -- 1847 Holdings LLC (OTC: LBRA) (“1847” or the “Company”), a diversified acquisition holding company focused on identifying and monetizing overlooked, deep-value businesses, today announced that its wholly owned subsidiary, CMD, Inc. (“CMD”), has been awarded over $4 million in new contracts, with an additional pipeline ...

LONDON, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced participation in a series of industry conferences and trade programs in March and April 2026. These events provide multiple platforms to engage stakeholders across ...

CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be avail ...

Core Insights - PMV Pharmaceuticals announced the publication of Phase 1 results for rezatapopt in the New England Journal of Medicine, demonstrating its potential in treating advanced solid tumors with a TP53 Y220C mutation [1][2][4] Group 1: Study Results - The Phase 1 portion of the PYNNACLE clinical trial involved 77 heavily pretreated patients, focusing on safety, pharmacokinetics, and determining the maximum tolerated dose of rezatapopt [3][6] - Objective responses were observed across multiple tumor types, with clinical activity linked to selective binding to the Y220C pocket and restoration of wild-type p53 function [3] - The overall response rate (ORR) across all cohorts was 34% (35 out of 103 patients), with a 46% ORR (22 out of 48 patients) specifically in ovarian cancer [4] Group 2: Drug Information - Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate p53 by selectively binding to the p53 Y220C mutant protein [5] - The FDA has granted Fast Track designation to rezatapopt for treating locally advanced or metastatic solid tumors with a p53 Y220C mutation [5] Group 3: Future Plans - The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027 [4] - The ongoing Phase 2 portion of the PYNNACLE trial aims to evaluate the efficacy of rezatapopt in various solid tumors with TP53 Y220C and KRAS wild-type mutations [6]